178
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Comparison of Efficacy and Safety of Loteprednol Etabonate 0.5% and Topical Dexamethasone 1% in Post-Vitrectomy Inflammation

, MD, , MD ORCID Icon, , MD & , MD
Pages 312-318 | Received 06 Apr 2017, Accepted 23 Nov 2017, Published online: 28 Dec 2017

References

  • El-Harazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2001;12:4–8.
  • Mohammadpour M, Jafarinasab MR, Javadi MA. Outcomes of acute postoperative inflammation after cataract surgery. Eur J Ophthalmol. 2007;17:20–28.
  • Campos, M., Ávila, M, Wallau, A, et al. Efficacy and tolerability of a fixed-dose moxifloxacin – dexamethasone formulation for topical prophylaxis in LASIK: A comparative, double-masked clinical trial. Clin Ophthalmol. 2008;2:331–338.
  • Holland EJ, Djalilian AR, Sanderson JP. Attenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantation. Cornea. 2009;28:1139–1143.
  • Seah SK, Husain R, Gazzard G, et al. Use of surodex in phacotrabeculectomy surgery. Am J Ophthalmol. 2005;139:927–928.
  • Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol. 1999;127:537–544.
  • Grigorian RA, Shah A, Guo S. Comparison of loteprednol etabonate 0.5% (Lotemax) to prednisolone acetate 1% (Falcon) for inflammation treatment following cataract surgery. Invest Ophthalmol Vis Sci. 2007;48:1065.
  • Kaur R, Matreja PS, Khan B, Bhatnagar RN. Compare the safety and efficacy of loteprendol etabonate 0.5% and prednisolone acetate 1% in the post operative inflammation following cataract extraction with intra ocular lens (IOL) implant. Ann Appl Bio-Sci. 2015;2: 106–110.
  • Lane SS, Holland EJ. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J Cataract Refract Surg. 2013;39:168–173.
  • Frangie JP, Leibowitz HM. Steroids. Int Ophthalmol Clin. 1993;33:9–29.
  • Bielory L. Ocular allergy treatment. Immunol Allergy Clin North Am. 2008;28:189–224, vii.
  • A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2. Ophthalmol. 1998;105:1780–1786.
  • Assil KK, Massry G, Lehmann R, Fox K, Stewart R. Control of ocular inflammation after cataract extraction with rimexolone 1% ophthalmic suspension. J Cataract Refract Surg. 1997;23:750–757.
  • Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009;35:26–34.
  • Druzgala P, Hochhaus G, Bodor N. Soft drugs–10. Blanching activity and receptor binding affinity of a new type of glucocorticoid: loteprednol etabonate. J Steroid Biochem Mol Biol. 1991;38:149–154.
  • Pirouzian A, Craven ER. Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery. Clin Ophthalmol. 2014;8:379–387.
  • Albert M, Wu. W, Winwood D, Bodor N. Lipophilicity, solubility and permeability of loteprednol etabonate: a novel, soft anti-inflammatory steroid. J Biopharm Sci. 1991;2:115–125.
  • Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
  • Scott J, Huskisson EC. Vertical or horizontal visual analogue scales. Ann Rheum Dis. 1979;38:560.
  • Amon M, Busin M. Loteprednol etabonate ophthalmic suspension 0.5%: efficacy and safety for postoperative anti-inflammatory use. Int Ophthalmol. 2012;32:507–517.
  • Wilson ME, O’Halloran H, VanderVeen D, et al. Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. Eye (Lond). 2016;30:1187–1194.
  • Sheppard JD, Comstock TL, Cavet ME. Impact of the topical ophthalmic corticosteroid loteprednol etabonate on intraocular pressure. Adv Ther. 2016;33:532–552.
  • Yu JG, Ni F, Xiang, Y., et al. A prospective study on postoperative discomfort after 20-gauge pars plana vitrectomy. Clin Ophthalmol. 2015;9:1379–1384.
  • Comstock TL, Usner DL, Effect of Loteprednol Etabonate Ophthalmic Suspension 0.5% on Post-Operative Pain and Discomfort. Poster presented at the American Society of Cataract and Refractive Surgery Annual Symposium, Boston, Massachusetts, USA, April 9–14, 2010.
  • Jonas JB, Knorr HL, Rank RM, Budde WM. Intraocular pressure and silicone oil endotamponade. J Glaucoma. 2001;10:102–108.
  • Chang S, Lincoff HA, Coleman DJ, Fuchs W, Farber ME. Perfluorocarbon gases in vitreous surgery. Ophthalmol. 1985;92:651–656.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.